A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
about
Biosynthesis of 4-aminoheptose 2-epimers, core structural components of the septacidins and spicamycins.Transforming pain medicine: adapting to science and societyNatural product and natural product derived drugs in clinical trials.d-Sedoheptulose-7-phosphate is a common precursor for the heptoses of septacidin and hygromycin B.
P2860
A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A spicamycin derivative (KRN55 ...... olled, proof-of-concept trial.
@en
A spicamycin derivative (KRN55 ...... olled, proof-of-concept trial.
@nl
type
label
A spicamycin derivative (KRN55 ...... olled, proof-of-concept trial.
@en
A spicamycin derivative (KRN55 ...... olled, proof-of-concept trial.
@nl
prefLabel
A spicamycin derivative (KRN55 ...... olled, proof-of-concept trial.
@en
A spicamycin derivative (KRN55 ...... olled, proof-of-concept trial.
@nl
P2093
P1476
A spicamycin derivative (KRN55 ...... olled, proof-of-concept trial.
@en
P2093
Andrea True Kelly
Isadore M Pike
Linda G Jett
Sharon M Weinstein
Susan E Spruill
P304
P356
10.1016/J.JPAINSYMMAN.2011.05.003
P577
2011-10-07T00:00:00Z